The newly established EU–India Trade Agreement represents a watershed moment for the pharmaceutical and biotech sectors across both regions.
What This Means for the Industry:
- Reduced trade barriers – enabling smoother cross-border operations
- Enhanced regulatory cooperation – streamlining approval pathways
- Strengthened IP protections – safeguarding innovation
- Resilient supply chains – reducing dependency risks
- Accelerated market access – reaching patients faster
This agreement creates unprecedented opportunities for companies to scale innovation, optimize manufacturing costs, and expand their therapeutic reach across Europe and India.
The Challenge? Execution.
Capitalizing on these opportunities demands more than market access—it requires deep regulatory expertise, operational agility, and on-the-ground knowledge of both ecosystems.
How We Help:
At Universal Medica Group, we partner with pharmaceutical and biotech companies to navigate this evolving landscape:
Regulatory strategy & Compliance Pharmacovigilance & Medical Information Market Access & Introduction Training GxP and Quality Management
Our teams bridge European and Indian regulatory environments, helping you move from strategy to execution—accelerating timelines, mitigating risk, and turning policy shifts into competitive advantage.
As the EU–India partnership deepens, we’re committed to helping our clients not just adapt to change, but fully exploit the opportunities it creates for sustainable growth, breakthrough innovation, and improved patient access worldwide.
